Nasdaq dbtx.

Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...

Nasdaq dbtx. Things To Know About Nasdaq dbtx.

Feb 12, 2021 · Director. 02/17/2021. Acquisition (Non Open Market) Indirect. 3,278,526. 2,732,106. Back to DBTX Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the ... BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Cynthia Hu, J.D., as Chief Legal Officer and Corporate Secretary.Decibel Therapeutics, Inc. Common Stock (DBTX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

NASDAQ:DBTX Decibel Therapeutics (DBTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively …

The Decibel Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.(DBTX) reported a total revenue of $12.5 million in the first quarter of 2022 ... NASDAQ · NYSE · Blog. Need Help? [email protected]. Create your mobile categories ...(NASDAQ: DBTX), Ear Diseases; Gene Therapy, Citigroup SVB Leerink BMO Capital Markets Barclays Capital, 2/11/2021. S-1, $18, $127 million, $16 – $18 ...BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug …BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a ...

Major Sales, Dec 2021, Decibel Therapeutics. Major sales ($100,000 or more). Decibel Therapeutics (NASDAQ: DBTX). View Major Sales. Related Products: Custom ...

DROPBOX INC ( DBX) is a mid-cap growth stock in the Software & Programming industry. The rating using this strategy is 93% based on the firm’s underlying fundamentals and the stock’s valuation ...

The average one-year price target for Decibel Therapeutics (NASDAQ:DBTX) has been revised to 14.69 / share. This is an increase of 9.37% from the prior estimate of 13.43 dated June 1, 2023. BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Translating rapid advances in hearing science to meet the urgent needs of hundreds of millions worldwide with disabling hearing loss.Nov 22, 2021 · Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss. Decibel Therapeutics ( NASDAQ: DBTX) said its clinical trial application (CTA) received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for starting a phase 1/2 ...

DBTX Latest Real Time Trades. Select time range to see more trades: Last 100 Trades. NLS Time (ET) NLS Price. NLS Share Volume. 16:00:04. $ 4.33. 42.Nov 27, 2023 · 5 analysts have issued 1 year price targets for Decibel Therapeutics' shares. Their DBTX share price targets range from $2.00 to $23.00. On average, they predict the company's share price to reach $8.45 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View analysts price targets for DBTX or ... BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...August 09 2023 - 08:14AMDow Jones News. By Dean Seal. Regeneron Pharmaceuticals agreed to acquire Decibel Therapeutics for $4 a share, marking a 43% …Aug 14, 2023 · Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...

Find the latest dividend history for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.

BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Sep 12, 2023 · Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ... To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ...Find the latest press releases from Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data ...25-Sept-2023 ... Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN): Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of ...BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement ...BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Shareholders will receive $4.0000 and 1 share of DBTX^ for each share of DBTX previously held. ... NASDAQ. Copy link to clipboard. June 1, 2021. June 1, 2021.

Jun 28, 2022 · BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a ...

BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of …BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...May 10, 2023 · BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday.May 10, 2023 · BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... 10-Nov-2023 ... ... NASDAQ:DBTX),一家致力于发现和开发恢复和改善听力和平衡的变革性治疗方法的临床生物技术公司,并附带一项额外的不可交易或有价值权(CVR),在 ...Aug 28, 2023 · Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ... (DBTX) reported a total revenue of $12.5 million in the first quarter of 2022 ... NASDAQ · NYSE · Blog. Need Help? [email protected]. Create your mobile categories ...

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. Common Stock (DBTX) Historical Closing Prices - View free historical Nasdaq official closing price data at Nasdaq.com.BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data ...Instagram:https://instagram. tradovate mobile apppeace by chocolate candybest vanguard funds retirementbionoid 18-Sept-2023 ... Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender ...Back to DBTX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following … polestar self drivingsldp quote Nov 30, 2023 · Decibel Therapeutics Description. Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support ... regions bank news IPO lockups expire on Signify Health (SGFY), Viant Technology , Apria (APR), Bumble , Bioventus , LoanDepot , Decibel Therapeutics (NASDAQ:DBTX), NexImmune and Talis Biomedical .BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Quick Take. Decibel Therapeutics (NASDAQ:DBTX) has filed to raise $100 million in an IPO of its common stock, according to an amended S-1 registration …